Topics

Merck BrightLab inventory management platform

19:00 EST 11 Feb 2020 | Australian Life Scientist

Merck has introduced its BrightLab cloud-based inventory management and instrument connectivity platform for research scientists. The software includes an electronic lab notebook, which allows scientists and lab managers to track and update experiments from any computer or mobile device. By centralising essential research information, the platform is designed to empower scientists to be more productive, save time and avoid errors.

Recognising the increasing demand for data automation, the software connects lab instruments to the cloud via application programming interface and Internet of Things (IoT) integrations, avoiding the need for manual transcription. This should save researchers hours of unnecessary review, allowing for more time at the bench. The platform also automates workflows and produces a secure, searchable archive of reports. All information on the cloud is accessible to only to designated users since the platform is designed with SSL encryption and provides data integrity with audit trails and regular backups built in.

The platform recognises that every lab has its own devices, so it connects with a growing library of supported instruments. Once set up, scientists can search data across projects and experiments. Lab equipment maintenance reminders, calibrations and protocols are saved in one place to stay organised and, ultimately, speed up the discovery process.

The platform is available at no charge to individual lab customers in academia. For those in the industry, a 30-day free trial is available to test the product and gain familiarity with its core lab function optimisation features.

Original Article: Merck BrightLab inventory management platform

NEXT ARTICLE

More From BioPortfolio on "Merck BrightLab inventory management platform"

Quick Search

Relevant Topic

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...